secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bicara Therapeutics Inc. (BCAX)
CIK:        0002023658
Form:       8-K
Filed at:   2026-06-10T20:05:24+00:00
Accession:  0001628280-26-042176
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Bicara Therapeutics stockholders elect directors and ratify KPMG as auditor
---------------------------------------------------------------------------

- Elected Dr. Christopher Bowden and Dr. Carolyn Ng as Class II directors for three-year terms.
- Bowden: 48,558,710 for, 5,145,418 withheld; Ng: 47,431,269 for, 6,272,859 withheld.
- Ratified KPMG LLP as independent auditor for FY2026: 55,914,602 for, 8,815 against, 1,570 abstain.
- 85.25% of outstanding shares (55.9M of 65.6M) were present or represented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023658/000162828026042176/0001628280-26-042176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023658/000162828026042176/bcax-20260609.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-042176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer